Antengene Corporation Limited (HKG:6996)

Market Cap	2.66B +298.9%
Revenue (ttm)	92.43M +50.4%
Net Income	-250.49M
EPS	-0.40
Shares Out	679.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,184,393
Average Volume	3,730,647
Open	3.870
Previous Close	3.860
Day's Range	3.670 - 3.980
52-Week Range	2.100 - 8.160
Beta	0.84
RSI	59.62
Earnings Date	Mar 24, 2026

About Antengene Corporation

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 152
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6996

Financial Performance

In 2024, Antengene Corporation's revenue was 91.95 million, an increase of 36.62% compared to the previous year's 67.31 million. Losses were -319.25 million, -45.07% less than in 2023.

Financial numbers in CNY